Company AnnouncementJanuary 27, 2026
Baseline Therapeutics Launches to Advance GLP-1RA Phase 3 Program in Alcohol Use Disorder
Clinical-stage biotechnology company announces launch to develop next-generation pharmacotherapies for substance use disorders.
Read more →